Linda Cox
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Linda Cox has a total of 378 co-authors. Here are the top co-authors by number of shared publications:
- Désirée Larenas-Linnemann
Centro de Excelencia en Asma y Alergia Larenas, Hospital Médica Sur, Mexico City, Mexico
3 shared publications - Enrico Compalati
Allergy and Respiratory Diseases Clinic, Department of Internal Medicine, University of Genoa, Genova, Italy
3 shared publications - Giorgio Walter Canonica
Personalized Medicine, Asthma and Allergy Humanitas Clinical & Research Center, IRCCS Rozzano Italy
3 shared publications - Moises A. Calderon
Section of Allergy and Clinical Immunology, Imperial College London, London, UK
3 shared publications - Pascal Demoly
University Hospital of Montpellier
3 shared publications Cheryl Hankin
BioMedicon, Ft Lauderdale, Fla
2 shared publications
Latest Publications
- 10 April 2023
- Published by Springer Nature in Current Treatment Options in Allergy
- Vol. 10 (2) , 184-195
Dance Is a Healing Art
Opinion Statement The purpose of this review is to evaluate the health benefits of dance and dance therapy in various health domains. Dance interventions included movement therapy with certified therapists, common dances such as ballroom dancing, salsa, and cha-cha as well as ethnic dances, such as the Chinese Guozhuang Dance and the Native American jingle dance. The health domains included depression, cognitive function, neuromotor function, dementia, balance, neurological growth factors, and subjective well-being. The National Library of Medicine, Congress of Library, and the Internet were searched using the terms: dance, dance movement therapy, health, cognitive function, healing, neurological function, neuromotor function, and affective disorders from 1831 to January 2, 2023. Two-thousand five hundred and ninety-one articles were identified. Articles were selected if they provided information on the health benefits of dance in one or more of the above domains as compared to a “non-dance” control population. Studies included systematic reviews, randomized controlled studies, and long-term perspective studies. Most of the subjects in the studies were considered “elderly,” which was generally defined as 65 years or older. However, the benefits of DI on executive function were also demonstrated in primary school children. Overall, the studies demonstrated that DI provided benefits in several physical and psychological parameters as well as executive function as compared with regular exercise alone. Impressive findings were that dance was associated with increased brain volume and function and neurotrophic growth function. The populations studied included subjects who were “healthy” older adults and children who had dementia, cognitive dysfunction, Parkinson’s disease, or depression.
- 10 April 2023
- Published by Springer Nature in Current Treatment Options in Allergy
- Vol. 10 (2) , 184-195
Dance Is a Healing Art
Opinion Statement The purpose of this review is to evaluate the health benefits of dance and dance therapy in various health domains. Dance interventions included movement therapy with certified therapists, common dances such as ballroom dancing, salsa, and cha-cha as well as ethnic dances, such as the Chinese Guozhuang Dance and the Native American jingle dance. The health domains included depression, cognitive function, neuromotor function, dementia, balance, neurological growth factors, and subjective well-being. The National Library of Medicine, Congress of Library, and the Internet were searched using the terms: dance, dance movement therapy, health, cognitive function, healing, neurological function, neuromotor function, and affective disorders from 1831 to January 2, 2023. Two-thousand five hundred and ninety-one articles were identified. Articles were selected if they provided information on the health benefits of dance in one or more of the above domains as compared to a “non-dance” control population. Studies included systematic reviews, randomized controlled studies, and long-term perspective studies. Most of the subjects in the studies were considered “elderly,” which was generally defined as 65 years or older. However, the benefits of DI on executive function were also demonstrated in primary school children. Overall, the studies demonstrated that DI provided benefits in several physical and psychological parameters as well as executive function as compared with regular exercise alone. Impressive findings were that dance was associated with increased brain volume and function and neurotrophic growth function. The populations studied included subjects who were “healthy” older adults and children who had dementia, cognitive dysfunction, Parkinson’s disease, or depression.
- Open Access
- 5 August 2021
- Published by Frontiers Media SA in Frontiers in Allergy
- Vol. 2, 710345
Grand Challenges in Allergen Immunotherapy
Grand Challenges in Allergen Immunotherapy
- 5 August 2021
- Published by Frontiers Media SA in Frontiers in Allergy
- Vol. 2, 710345
Open AccessGrand Challenges in Allergen Immunotherapy
Grand Challenges in Allergen Immunotherapy
- 28 February 2021
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 17 (3) , 255-268
Pharmacoeconomics of allergy immunotherapy versus pharmacotherapy
Introduction: The purpose of this review is to evaluate the cost-effectiveness of allergy immunotherapy (AIT) in the treatment of allergic rhinitis, asthma, and other allergic conditions. Area covered: An extensive search of the PubMed and Medline database (January 1996 up to June of 2020) was conducted using the search terms allergy immunotherapy, pharmacoeconomics, cost-effectiveness, allergic rhinitis, and asthma. Studies were included if they included information on the economics of AIT in comparison to pharmacotherapy in the treatment of allergic rhinitis or asthma either as actual costs or based on theoretical models. Systematic reviews were included if they included information about the cost-effectiveness of AIT. Most clinical trials found significant cost-savings with AIT. The cost-effective time-point ranged from a few months to several years after treatment initiation.. Cost savings were demonstrated as early as 3 months after treatment initiation and were as great as 80% less than SDT in some studies. Expert opinion: There is strong evidence in the collective literature that AIT is cost-effective as compared to SDT alone. The magnitude of AIT’s cost-effectiveness is likely underestimated because most of the studies considered during treatment costs and not AIT’s long-term benefits or preventive/prophylactic effects or its impact on co-morbid conditions.
- 28 February 2021
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 17 (3) , 255-268
Pharmacoeconomics of allergy immunotherapy versus pharmacotherapy
Introduction: The purpose of this review is to evaluate the cost-effectiveness of allergy immunotherapy (AIT) in the treatment of allergic rhinitis, asthma, and other allergic conditions. Area covered: An extensive search of the PubMed and Medline database (January 1996 up to June of 2020) was conducted using the search terms allergy immunotherapy, pharmacoeconomics, cost-effectiveness, allergic rhinitis, and asthma. Studies were included if they included information on the economics of AIT in comparison to pharmacotherapy in the treatment of allergic rhinitis or asthma either as actual costs or based on theoretical models. Systematic reviews were included if they included information about the cost-effectiveness of AIT. Most clinical trials found significant cost-savings with AIT. The cost-effective time-point ranged from a few months to several years after treatment initiation.. Cost savings were demonstrated as early as 3 months after treatment initiation and were as great as 80% less than SDT in some studies. Expert opinion: There is strong evidence in the collective literature that AIT is cost-effective as compared to SDT alone. The magnitude of AIT’s cost-effectiveness is likely underestimated because most of the studies considered during treatment costs and not AIT’s long-term benefits or preventive/prophylactic effects or its impact on co-morbid conditions.
- 1 May 2020
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 40 (2) , XIII-XV
Rhinosinusitis Diagnosis and Management: The Hoops and Hurdles Foreword
- 1 May 2020
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 40 (2) , XIII-XV
Rhinosinusitis Diagnosis and Management: The Hoops and Hurdles Foreword
- 1 February 2020
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 40 (1) , XIII-XIV
Allergy Immunotherapy: Are We Making Progress or Just Standing Still?
- 1 February 2020
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 40 (1) , XIII-XIV
Allergy Immunotherapy: Are We Making Progress or Just Standing Still?
- 19 November 2019
- Published by Elsevier in Medical Clinics of North America
- Vol. 104 (1) , 77-94
Approach to Patients with Allergic Rhinitis
- 19 November 2019
- Published by Elsevier in Medical Clinics of North America
- Vol. 104 (1) , 77-94
Approach to Patients with Allergic Rhinitis
- 1 January 2017
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 5 (1) , 58-62.e5
World Allergy Organization Systemic Allergic Reaction Grading System: Is a Modification Needed?
- 1 January 2017
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 5 (1) , 58-62.e5
World Allergy Organization Systemic Allergic Reaction Grading System: Is a Modification Needed?
- 1 January 2017
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 5 (1) , 63-65
Sublingual Immunotherapy: Historical Perspective and Practical Guidance
- 1 January 2017
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 5 (1) , 63-65
Sublingual Immunotherapy: Historical Perspective and Practical Guidance
- Open Access
- 30 December 2016
- Published by Wiley in Clinical and Translational Allergy
- Vol. 6 (1) , 1-14
ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle
The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA—disseminated and implemented in over 70 countries globally—is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.
- 30 December 2016
- Published by Wiley in Clinical and Translational Allergy
- Vol. 6 (1) , 1-14
Open AccessARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle
The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA—disseminated and implemented in over 70 countries globally—is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.